Skip to content

TRV GP V, LLC

Follow

13F filer, CIK 1990717, Boston, MA

TRV GP V, LLC reported $474,980,000 across 4 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16.

Accepted , ingested 13F-HR 0001193125-26-463550

Period
2026-09-30
Reported value
$475M
Holdings
4
Top 10 weight
100%
New
1
Sold out
0

Part of the filer group Third Rock Ventures VI, L.P.

How groups are built

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • TCXB TCGX ACQUISITION CORP II: 13G 990,000 shares, 9.5% of the class, 13G filed 2026-10-26, 0001193125-26-432002Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
LSTAnew+455,192$655K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SEPNreduced-147,200-$5.76M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001193125-26-463550, largest first. % of portfolio is the value over $474,980,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,215,591 shares; 2025Q1: 6,215,591 shares; 2025Q2: 6,215,591 shares; 2025Q3: 6,215,591 shares; 2025Q4: 6,215,591 shares; 2026Q1: 6,215,591 shares; 2026Q2: 6,215,591 shares; 2026Q3: 6,068,391 shares 6,068,391$237M49.99%-147,200Timeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 7,135,233 shares; 2025Q1: 7,135,233 shares; 2025Q2: 7,135,233 shares; 2025Q3: 7,135,233 shares; 2025Q4: 7,135,233 shares; 2026Q1: 7,135,233 shares; 2026Q2: 6,280,525 shares; 2026Q3: 6,280,525 shares 6,280,525$211M44.43%02026-10-30, Form 4: granted 238,095 shares on 2026-10-30 Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 950,800 shares; 2025Q2: 950,800 shares; 2025Q3: 950,800 shares; 2025Q4: 950,800 shares; 2026Q1: 950,800 shares; 2026Q2: 950,800 shares; 2026Q3: 950,800 shares 950,800$25.8M5.44%0Timeline
LSTALISATA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 455,192 shares 455,192$655K0.14%newTimeline

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-463550 base2026-11-16